Literature DB >> 25404023

Critical roles of Clostridium difficile toxin B enzymatic activities in pathogenesis.

Shan Li1, Lianfa Shi1, Zhiyong Yang1, Yongrong Zhang1, Gregorio Perez-Cordon1, Tuxiong Huang1, Jeremy Ramsey1, Numan Oezguen2, Tor C Savidge2, Hanping Feng3.   

Abstract

TcdB is one of the key virulence factors of Clostridium difficile that is responsible for causing serious and potentially fatal colitis. The toxin contains at least two enzymatic domains: an effector glucosyltransferase domain for inactivating host Rho GTPases and a cysteine protease domain for the delivery of the effector domain into host cytosol. Here, we describe a novel intrabody approach to examine the role of these enzymes of TcdB in cellular intoxication. By screening a single-domain heavy chain (V(H)H) library raised against TcdB, we identified two V(H)H antibodies, 7F and E3, that specifically inhibit TcdB cysteine protease and glucosyltransferase activities, respectively. Cytoplasmic expression of 7F intrabody in Vero cells inhibited TcdB autoprocessing and delayed cellular intoxication, whereas E3 intrabody completely blocked the cytopathic effects of TcdB holotoxin. These data also demonstrate for the first time that toxin autoprocessing occurs after cysteine protease and glucosyltransferase domains translocate into the cytosol of target cells. We further determined the role of the enzymatic activities of TcdB in in vivo toxicity using a sensitive systemic challenge model in mice. Consistent with these in vitro results, a cysteine protease noncleavable mutant, TcdB-L543A, delayed toxicity in mice, whereas glycosyltransferase-deficient TcdB demonstrated no toxicity up to 500-fold of the 50% lethal dose (LD50) when it was injected systemically. Thus, glucosyltransferase but not cysteine protease activity is critical for TcdB-mediated cytopathic effects and TcdB systemic toxicity, highlighting the importance of targeting toxin glucosyltransferase activity for future therapy.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25404023      PMCID: PMC4294253          DOI: 10.1128/IAI.02316-14

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  62 in total

1.  Point mutations alter the mechanical stability of immunoglobulin modules.

Authors:  H Li; M Carrion-Vazquez; A F Oberhauser; P E Marszalek; J M Fernandez
Journal:  Nat Struct Biol       Date:  2000-12

2.  Single-domain antibody fragments with high conformational stability.

Authors:  Mireille Dumoulin; Katja Conrath; Annemie Van Meirhaeghe; Filip Meersman; Karel Heremans; Leon G J Frenken; Serge Muyldermans; Lode Wyns; Andre Matagne
Journal:  Protein Sci       Date:  2002-03       Impact factor: 6.725

3.  Cellular uptake of Clostridium difficile toxin B. Translocation of the N-terminal catalytic domain into the cytosol of eukaryotic cells.

Authors:  Gunther Pfeifer; Jörg Schirmer; Jost Leemhuis; Christian Busch; Dieter K Meyer; Klaus Aktories; Holger Barth
Journal:  J Biol Chem       Date:  2003-08-26       Impact factor: 5.157

4.  Low pH-induced formation of ion channels by clostridium difficile toxin B in target cells.

Authors:  H Barth; G Pfeifer; F Hofmann; E Maier; R Benz; K Aktories
Journal:  J Biol Chem       Date:  2001-01-04       Impact factor: 5.157

5.  Translocation domain mutations affecting cellular toxicity identify the Clostridium difficile toxin B pore.

Authors:  Zhifen Zhang; Minyoung Park; John Tam; Anick Auger; Greg L Beilhartz; D Borden Lacy; Roman A Melnyk
Journal:  Proc Natl Acad Sci U S A       Date:  2014-02-24       Impact factor: 11.205

Review 6.  Microbes and microbial toxins: paradigms for microbial-mucosal interactions II. The integrated response of the intestine to Clostridium difficile toxins.

Authors:  C Pothoulakis; J T Lamont
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2001-02       Impact factor: 4.052

7.  pH-induced conformational changes in Clostridium difficile toxin B.

Authors:  M Qa'Dan; L M Spyres; J D Ballard
Journal:  Infect Immun       Date:  2000-05       Impact factor: 3.441

8.  Clostridium difficile toxin B activates dual caspase-dependent and caspase-independent apoptosis in intoxicated cells.

Authors:  Maen Qa'Dan; Matthew Ramsey; Jeremy Daniel; Lea M Spyres; Barbara Safiejko-Mroczka; William Ortiz-Leduc; Jimmy D Ballard
Journal:  Cell Microbiol       Date:  2002-07       Impact factor: 3.715

9.  Pyknotic cell death induced by Clostridium difficile TcdB: chromatin condensation and nuclear blister are induced independently of the glucosyltransferase activity.

Authors:  Katharina Wohlan; Sebastian Goy; Alexandra Olling; Sangar Srivaratharajan; Helma Tatge; Harald Genth; Ralf Gerhard
Journal:  Cell Microbiol       Date:  2014-08-04       Impact factor: 3.715

10.  LRP1 is a receptor for Clostridium perfringens TpeL toxin indicating a two-receptor model of clostridial glycosylating toxins.

Authors:  Björn Schorch; Shuo Song; Ferdy R van Diemen; Hans H Bock; Petra May; Joachim Herz; Thijn R Brummelkamp; Panagiotis Papatheodorou; Klaus Aktories
Journal:  Proc Natl Acad Sci U S A       Date:  2014-04-15       Impact factor: 11.205

View more
  19 in total

1.  A small-molecule antivirulence agent for treating Clostridium difficile infection.

Authors:  Kristina Oresic Bender; Megan Garland; Jessica A Ferreyra; Andrew J Hryckowian; Matthew A Child; Aaron W Puri; David E Solow-Cordero; Steven K Higginbottom; Ehud Segal; Niaz Banaei; Aimee Shen; Justin L Sonnenburg; Matthew Bogyo
Journal:  Sci Transl Med       Date:  2015-09-23       Impact factor: 17.956

2.  The chaperonin TRiC/CCT is essential for the action of bacterial glycosylating protein toxins like Clostridium difficile toxins A and B.

Authors:  Marcus Steinemann; Andreas Schlosser; Thomas Jank; Klaus Aktories
Journal:  Proc Natl Acad Sci U S A       Date:  2018-09-04       Impact factor: 11.205

3.  The role of purified Clostridium difficile glucosylating toxins in disease pathogenesis utilizing a murine cecum injection model.

Authors:  Yongrong Zhang; Zhiyong Yang; Si Gao; Therwa Hamza; Harris G Yfantis; Michael Lipsky; Hanping Feng
Journal:  Anaerobe       Date:  2017-10-12       Impact factor: 3.331

4.  Pathology after Chlamydia trachomatis infection is driven by nonprotective immune cells that are distinct from protective populations.

Authors:  Rebeccah S Lijek; Jennifer D Helble; Andrew J Olive; Kyra W Seiger; Michael N Starnbach
Journal:  Proc Natl Acad Sci U S A       Date:  2018-02-09       Impact factor: 11.205

Review 5.  The role of toxins in Clostridium difficile infection.

Authors:  Ramyavardhanee Chandrasekaran; D Borden Lacy
Journal:  FEMS Microbiol Rev       Date:  2017-11-01       Impact factor: 16.408

6.  Glucosyltransferase activity of Clostridium difficile Toxin B is essential for disease pathogenesis.

Authors:  Zhiyong Yang; Yongrong Zhang; Tuxiong Huang; Hanping Feng
Journal:  Gut Microbes       Date:  2015-06-19

7.  Murine Intrarectal Instillation of Purified Recombinant Clostridioides difficile Toxins Enables Mechanistic Studies of Pathogenesis.

Authors:  Nicholas O Markham; Sarah C Bloch; John A Shupe; Erin N Laubacher; Audrey K Thomas; Heather K Kroh; Kevin O Childress; F Christopher Peritore-Galve; M Kay Washington; Robert J Coffey; D Borden Lacy
Journal:  Infect Immun       Date:  2021-03-17       Impact factor: 3.441

8.  Treatment of Clostridium difficile Infection with a Small-Molecule Inhibitor of Toxin UDP-Glucose Hydrolysis Activity.

Authors:  Ilana L Stroke; Jeffrey J Letourneau; Teresa E Miller; Yan Xu; Igor Pechik; Diana R Savoly; Linh Ma; Laurie J Sturzenbecker; Joan Sabalski; Philip D Stein; Maria L Webb; David W Hilbert
Journal:  Antimicrob Agents Chemother       Date:  2018-04-26       Impact factor: 5.191

9.  Defective mutations within the translocation domain of Clostridium difficile toxin B impair disease pathogenesis.

Authors:  Therwa Hamza; Zhifen Zhang; Roman A Melnyk; Hanping Feng
Journal:  Pathog Dis       Date:  2015-10-26       Impact factor: 3.166

Review 10.  Pathogenic effects of glucosyltransferase from Clostridium difficile toxins.

Authors:  Yongrong Zhang; Hanping Feng
Journal:  Pathog Dis       Date:  2016-04-04       Impact factor: 3.166

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.